Three flags fluttering above the pavilion of London's Oval cricket ground neatly symbolised the interchangeable identities of Britain's ethnic minorities at the fourth Test between England and India on Thursday.
A British Union Jack flew highest in the middle, flanked by England's Saint George's Cross and an Indian tricolour, as the teams resumed a gripping five-match series tied at 1-1.
Despite being born and raised in the UK, many cricket fans of Indian origin came to cheer on Virat Kohli's men rather than Joe Root's England side.
"It gives us togetherness as friends and family -- it's not a tribal thing," explained financial adviser Ronak Paw, 38.
"It's our heritage. It's not like we hate England. When England play anyone else, we support England," he added.
Britain has a long history of immigration from Commonwealth countries including India, with large numbers arriving after World War II to fill labour shortages and rebuild the country.
Generations of British Asians have since become part of the fabric of society.
Finance minister Rishi Sunak is of Indian origin and 2.5 percent of people in England and Wales identified as ethnically Indian in the last census.
But a complex mix of cultural factors -- especially cricket's central place in Indian culture -- means many Britons with Indian heritage support the country of their forebears.
"Only as culture, cricket takes precedence. I support India for cricket purposes only," said retail worker Viren Patel, 55.
"It's a cultural thing, nothing to do with the country itself. I feel divided because 90 percent of the year you're supporting England," he added.
In 1990, former UK government minister Norman Tebbit announced a controversial benchmark to judge whether ethnic minorities had integrated into British society based on their cricketing loyalties.
- 'Tebbit has gone past his sell-by date' -
But the so-called "Tebbit test" dismayed numerous UK-born India fans who saw no contradiction between being British and backing India's cricket team.
"There's nothing to prove our commitment to Britain or England by supporting the national team," insisted Paw.
"We pay our taxes here, we were born here, we live here -- what proof do we need that we are British?"
Praveen Sangar, a 63-year-old engineer, proudly sported a dark blue India cricket shirt as someone born in India who moved to Britain aged five.
"In football you support England, in cricket I support my homeland -- there's no conflict," he said.
"The world is multi-national now. Norman Tebbit has gone past his sell-by date."
The debate divides opinion within minority communities as some cheer for their country of birth based on personal circumstances, often pitting them against friends and relatives.
Yet others see these fluid identities as a positive way of engaging minority communities in cricket, selling out stadiums and making the sport more accessible.
"It's a friendly rivalry. Cricket is competitive but everyone gets on with everyone. You can feel comfortable supporting whichever team," said marketing worker Jazz Sidha, 52.
"Where you live has nothing to do with your nationality or your heritage -- you cannot dictate that," he added.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.